welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

key information

study id #: NCT02907619

condition: Duchenne Muscular Dystrophy

status: terminated


This study is an open-label extension to protocol B5161002 and will provide an assessment of the long term safety, efficacy, pharmacodynamics and pharmacokinetics of intravenous dosing of PF 06252616 in boys with Duchenne muscular dystrophy. Approximately 105 eligible subjects will be assigned to receive a monthly individualized maximum tolerated dose based on their tolerability profile/data from B5161002. This study will not contain a placebo comparator. Subjects will undergo safety evaluations (Laboratory, cardiac monitoring, physical exams, x-ray, MRI), functional capacity evaluations (4 stair climb, range of motion, strength testing, Northstar Ambulatory Assessment, upper limb functional testing, six minute walk test and pulmonary function tests) and pharmacokinetic testing.

intervention: PF-06252616

mechanism of action: Monoclonal anti-myostatin to promote muscle growth and improve function

results: https://clinicaltrials.gov/ct2/show/results/NCT02907619

last updated: November 26, 2019